Poxel S. A., a biopharmaceutical firm in the clinical stage, is dedicated to creating innovative treatments for a range of metabolic disorders, including type 2 diabetes and various liver ailments. Its flagship product, Imeglimin, is an oral drug candidate that has successfully completed Phase III clinical trials in Japan.